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OBJECTIVES: Melanoma is the ﬁ rst mortality cause by skin cancer. The more 
advanced stages prognosis is remaining poor. The MELODY study had as primary 
objectives to describe the disease characteristics, treatment modalities/outcomes, and 
resources use in patients with unresectable Stage III-Stage IV (UNRSIII-SIV) mela-
noma. METHODS: MELODY was a three-country (France, Italy, UK) longitudinal, 
retrospective, observational survey. In the French cohort, 10 expert dermatology 
departments had to register all melanomas seen between July 2005 and June 2006. 
The UNRSIII-SIV cases, with minimum 2-month follow-up, were extracted for 
detailed description of the disease characteristics, treatments (systemic, local, sup-
portive care), and outcomes and resource use, until May 1, 2008 or death. RESULTS: 
In France, 1224 patients (pts) were registered, in which 278 UNRSIII-SIV cases were 
extracted. At initial diagnosis, 34/1224 pts (2.8%) were UNRSIII-SIV; 253 pts (91%) 
received systemic treatment, while 230 (91%) had a chemotherapy of any line. In 
ﬁ rst-line systemic (n = 249), 198 pts (80%) were treated outside clinical trials, in 
whom 119 (60%) were on dacarbazine (D) and 35 (18%) on fotemustine (F) mono-
therapy; complete/partial response was noted for 21 pts (11%), with 2.9-month 
median response duration, median of progression-free survival (PFS) was 2.8 months 
(2.6; 3.5). In second line, 159 pts (57%) were treated, in whom 139 (87%) outside 
of clinical trials, with 75 (54%) on F, and 16 (12%) on D; median PFS was 2.5 months 
(2.1; 3.9). In case of systemic treatment/supportive care, there was a median of 20 
(11; 30) hospitalization days (13 [6; 22] days for ﬁ rst line systemic) and 3 [1; 6] 
outpatient visits (1.5 [1.0; 5.0] for ﬁ rst-line systemic). CONCLUSIONS: In the French 
cohort of MELODY, chemotherapy treatments gave modest results in terms of com-
plete/partial response and PFS, at a high cost of resource use, highlighting the unmet 
medical need. 
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OBJECTIVES: The incidence of malignant melanoma has been continuously growing; 
however, early identiﬁ cation contributes signiﬁ cantly to its effective treatment. As a 
prerequisite, the individual needs to see a specialist soon after the recognition of the 
ﬁ rst symptoms. Therefore, the aim of our study is to disclose the factors and patient 
attitude behind seeing a specialist in case of skin deformation in order to establish the 
method for effective treatment. METHODS: Retrospective cross-sectional study was 
carried out among patients in four cities (n = 280) who had been diagnosed with 
malignant melanoma within 5 years. Besides sociodemographic data, the questionnaire 
focused on the awareness and knowledge of the patient regarding melanoma, on risk 
factors, the general attitude of seeing doctors, and that of delaying factors in respect 
of melanoma. Single and multiple logistic regression were used in statistical analysis. 
RESULTS: After the recognition of skin deformation, only half of the patients visit a 
doctor within 1 year. The increase of latency (seeing a specialist more than 3 months 
after the incidence of the ﬁ rst symptoms) was four to seven times more frequent among 
those who demonstrate anxiety and distress, feel exposed to doctors, lie in the sun 
without any control, lack awareness of the disease, and have a lower rate of social 
support (P < 0.01). The study also revealed the shortages of primary care (e.g., insuf-
ﬁ cient examination, lack of information supply). Seeing a specialist in most of the 
cases was motivated by external factors. CONCLUSIONS: To estimate the beneﬁ t of 
developing programs focusing on health behavior and awareness building of the 
prevalence and incidence of malignant melanoma instead of facilitating several preven-
tive interventional projects based on the screening of the population.
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OBJECTIVES: To identify the association of sociodemographic, resource use, and 
adverse events variables with adherence to measure the return on investment of a 
patient education service for colorectal cancer patients taking capecitabine. 
METHODS: This was a prospective intervention of government patients in the 
country of Mexico of any age, with colorectal cancer and capecitabine treatment. The 
intervention group had access to a hot line, booklets, nutritional and psychological 
support; control group patients did not. a structured ad-hoc questionnaire applied the 
Morisky–Green Test to determine adherence to therapy via follow-up phone calls. 
Associations between variables and adherence between intervention group and con-
trols were assessed using chi-square test. Emergency rooms (ER) visits were the eco-
nomic indicator to establish cost differences between groups. Power analysis was 
conducted using PS Power and Sample Size Calculations version 3.0, January 2009. 
RESULTS: A total of 220 patients were included in this study (mean age 58.4 [26 to 
89] years), 121 intervention patients (48 responded to ﬁ rst call; 70% adherence) and 
99 control patients (30 responded to ﬁ rst call; 57% adherence). If the true odds ratio 
for adherence in intervention relative to control is 1.86, a power analysis projects 
statistical signiﬁ cance with 290 intervention patients and 181 controls to reject the 
null hypothesis with a probability (power) of 0.8. The reason for nonadherence “Does 
not know administration regime” did show statistical signiﬁ cance (P = 0.019) between 
the intervention (10% n = 2) and control group (47% n = 7). For ER visits related to 
adverse events, the control group rate was 13.33% (n = 4) versus 2.32% (n = 1) in 
the intervention group (P = 0.067). The cost for ER/day is $Mex 1,144.44 (USD 
86.82). CONCLUSIONS: These preliminary results indicate that patients who receive 
intervention services may have improved adherence to medication and therefore fewer 
ER visits and costs. Continued enrollment will be able to determine true 
signiﬁ cance.
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OBJECTIVES: In the ToGA study, patients with HER2+ aGC (n = 584) who received 
trastuzumab + chemotherapy achieved signiﬁ cantly improved overall survival com-
pared to patients receiving chemotherapy alone (HR = 0.74 (95% CI 0.60; 0.91, P = 
0.0046; van Cutsem et al. 2009). Since published utilities in gastric cancer are rare, 
we report results of the EQ-5D analysis from ToGA here, particularly the obtained 
utility for progression-free-survival (PFS). METHODS: The EQ-5D was provided to 
patients at baseline and every 3 weeks until disease progression. The questionnaire 
was completed by the patient prior to any study speciﬁ c assessment or discussion with 
their study care provider. Patients’ EQ-5D responses were scored using UK-tariffs, 
according to the guidelines of the EuroQol group. Only fully completed questionnaires 
were included. Mixed effects random slope models in SAS v8.2 were developed to 
estimate the health state utility. The intercept and day of assessment were incorporated 
as random effects. Covariance structures were assessed for goodness of ﬁ t using Akaike 
Information Criteria. Secondary analyses that included a treatment indicator were 
performed to explore a possible treatment effect. EQ-5D analysis of a patient subgroup 
(with tumors highly expressing the HER2-protein, i.e., IHC3+ or IHC2+ and FISH+, 
metastatic at screening, n = 431), was also conducted. RESULTS: The unstructured 
covariance matrix was found to be the best ﬁ t and resulted into a PFS-utility of 0.73 
(95% CI: 0.71; 0.75). The treatment effect was not found to be signiﬁ cant (P = 
0.1542); i.e., no difference between the two treatment regimens was identiﬁ ed. Results 
were conﬁ rmed for the subgroup. CONCLUSIONS: Although only HER2+ patients 
were included in ToGA, the obtained utility value is in line with other published PFS-
utilities in aGC. Given the large patient numbers, 0.73 can be regarded as a robust 
estimate of a patient-reported outcome. Further studies in aGC should attempt to 
assess the utility in patients following disease progression.
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OBJECTIVES: In the UK, chronic lymphocytic leukemia (CLL) makes up 40% of all 
leukemias in patients over 65 years. The objective of this UK-based study was to obtain 
societal preferences for “progression-free” and “progressive” stages of late-stage CLL, 
and selected treatment-related adverse events. METHODS: A utility study, using the 
time-trade off (TTO) method, was conducted in the UK with 110 members of the 
general public for a baseline disease state (before treatment), three primary disease 
states (progression-free survival [PFS] response, PFS non-response, and disease pro-
gression) and four adverse event (AE) substates (PFS response with thrombocytopenia, 
neutropenia or severe infection, and PFS non-response with severe infection). Disease 
state vignettes were developed using literature and validated by expert CLL clinicians. 
Face-to-face interviews were conducted by trained interviewers. The TTO scores were 
converted into a utility value for each disease state and disutilities were calculated for 
AEs. Visual analogue scale (VAS) scores were also obtained. RESULTS: All partici-
pants were included in the analysis. The mean utility scores from the TTO for the 
primary disease states were: baseline: 0.549; PFS response: 0.671; PFS nonresponse: 
0.394; and progression: 0.294. The mean TTO utility (disutility) scores for the AEs 
were: PFS response with thrombocytopenia, neutropenia, or infection, 0.563 (−0.108), 
0.508 (−0.163), 0.476 (−0.195), respectively; PFS nonresponse with infection, 0.333 
(−0.061). The VAS results were in line with the TTO results. CONCLUSIONS: 
